Acquired mechanisms of immune escape in cancer following immunotherapy

J Bryan Iorgulescu; David Braun; Giacomo Oliveira; Derin B Keskin; Catherine J Wu

doi:10.1186/s13073-018-0598-2

Acquired mechanisms of immune escape in cancer following immunotherapy

Genome Med. 2018 Nov 22;10(1):87. doi: 10.1186/s13073-018-0598-2.

Authors

J Bryan Iorgulescu^{1

2

3

4}, David Braun^{1

2

4}, Giacomo Oliveira^{1

2}, Derin B Keskin^{1

2

5}, Catherine J Wu^{6

7

8}

Affiliations

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
² Harvard Medical School, Boston, MA, 02115, USA.
³ Department of Pathology, Brigham and Women's Hospital, Boston, MA, 02115, USA.
⁴ Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
⁵ Translational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.
⁶ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA. cwu@partners.org.
⁷ Harvard Medical School, Boston, MA, 02115, USA. cwu@partners.org.
⁸ Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA. cwu@partners.org.

Abstract

Immunotherapy has revolutionized the management of numerous cancers; however, a substantial proportion that initially respond subsequently acquire means of immune escape and relapse. Analysis of recent clinical trials permits us to preliminarily understand how immunotherapies exert evolutionary pressures: selecting cancer subclones deficient in antigenicity and/or immunogenicity, thereby facilitating immune escape.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Antigen Presentation
Humans
Immunotherapy*
Neoplasms / immunology*
Neoplasms / therapy*
Tumor Escape*

Abstract

Publication types

MeSH terms

Grants and funding